Light chain (AL) amyloidosis is a rare and progressive disease that interferes with normal organ function and lead to failure of vital organs, like the heart. Currently, there are no approved therapies that significantly improve survival.

The impact of amyloidosis goes beyond health. Patients with AL amyloidosis experience frequent overall loss of productivity, missed work or loss of employment. Understanding how AL amyloidosis affects work outcomes can help inform healthcare policies and treatments to reduce the burden on individuals, their families and society.

We at Prothena aim to recognize the challenges faced by those with rare disease to ensure their voices are heard and look forward to continuing the collaborative approach to advance the management of advanced AL amyloidosis. Learn more about how AL amyloidosis affects work outcomes here.